RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+8.38%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.6B
AUM Growth
+$1.6B
(-8.2%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-14.81%
Top 10 Holdings %
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$21.5M |
| 2 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$21.2M |
| 3 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$16.8M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$12.6M |
| 5 |
Arcellx
ACLX
|
$12.3M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$105M |
| 2 |
Nuvalent
NUVL
|
$25.5M |
| 3 |
Neurocrine Biosciences
NBIX
|
$23.9M |
| 4 |
Legend Biotech
LEGN
|
$17.4M |
| 5 |
UnitedHealth
UNH
|
$15.6M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $96.9M | 6.04% | 175,750 | – | – |
|
2
Eli Lilly
LLY
$657B
| $90.8M | 5.66% | 116,500 +3,000 | +3% | +$2.34M |
|
3
Merus
MRUS
$4.98B
| $55.9M | 3.49% | 1,063,608 +82,857 | +8% | +$4.36M |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $54.4M | 3.39% | 861,153 +26,965 | +3% | +$1.7M |
|
5
Insmed
INSM
$28.8B
| $52.8M | 3.29% | 525,000 +9,100 | +2% | +$916K |
|
6
Ultragenyx Pharmaceutical
RARE
$2.89B
| $50.6M | 3.15% | 1,391,072 -3,362 | -0.2% | -$122K |
|
7
Revolution Medicines
RVMD
$7.1B
| $49M | 3.05% | 1,330,960 +49,320 | +4% | +$1.81M |
|
8
Intuitive Surgical
ISRG
$170B
| $44.6M | 2.78% | 82,000 -20,000 | -20% | -$10.9M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $42.5M | 2.65% | 140,296 -26,402 | -16% | -$7.99M |
|
10
Mirum Pharmaceuticals
MIRM
$3.71B
| $41.6M | 2.59% | 818,206 -133,559 | -14% | -$6.8M |
|
11
Boston Scientific
BSX
$156B
| $38.1M | 2.38% | 355,000 +78,000 | +28% | +$8.38M |
|
12
Ascendis Pharma
ASND
$11.8B
| $37.5M | 2.33% | 217,000 +1,000 | +0.5% | +$173K |
|
13
iRhythm Technologies
IRTC
$5.46B
| $37.3M | 2.33% | 242,500 -11,800 | -5% | -$1.82M |
|
14
Akero Therapeutics
AKRO
$3.74B
| $34.2M | 2.13% | 640,526 -32,233 | -5% | -$1.72M |
|
15
Penumbra
PEN
$10.6B
| $33M | 2.05% | 128,500 -42,500 | -25% | -$10.9M |
|
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $32.9M | 2.05% | 989,745 +647,565 | +189% | +$21.5M |
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $32.6M | 2.03% | 100,000 -43,250 | -30% | -$14.1M |
|
18
Evolent Health
EVH
$1.12B
| $31.8M | 1.98% | 2,820,700 +125,000 | +5% | +$1.41M |
|
19
Zai Lab
ZLAB
$3.68B
| $30.5M | 1.9% | 871,392 -33,200 | -4% | -$1.16M |
|
20
Exact Sciences
EXAS
$8.98B
| $30.4M | 1.89% | 572,000 +92,000 | +19% | +$4.89M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $29.2M | 1.82% | 931,681 | – | – |
|
22
Travere Therapeutics
TVTX
$1.56B
| $28.2M | 1.76% | 1,908,208 -1,012,988 | -35% | -$15M |
|
23
Scholar Rock
SRRK
$3.14B
| $28.1M | 1.75% | 794,133 +32,592 | +4% | +$1.15M |
|
24
DexCom
DXCM
$29.5B
| $25M | 1.56% | 286,750 -110,900 | -28% | -$9.68M |
|
25
Phreesia
PHR
$1.88B
| $23.8M | 1.48% | 837,300 -311,036 | -27% | -$8.85M |
|